Do not stop taking Plavix without first talking to your doctor, even if you have signs of bleeding. Stopping the medicine could increase your risk of a heart attack or stroke. There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease and stroke. For patients with suboptimal response to clopidogrel, consider alternative P2Y12 inhibitors to reduce thrombotic risk, particularly in high-risk settings such as recent acute coronary syndrome or complex percutaneous coronary intervention. UpToDate. In this ever-changing scenario, numerous studies have addressed 4 main questions regarding P2Y 12 inhibition in ACS patients undergoing PCI: timing, selection, modulation, and duration. Concomitant use of certain inhibitors of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor. Dose dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix. Repeated doses of 75 mg Plavix per day inhibit ADP-induced platelet aggregation on. Clopidogrel, a commonly used antiplatelet, faces challenges such as genetic variability in metabolism and drug–drug interactions, impacting its effectiveness. Other agents, such as ticagrelor and prasugrel, offer alternatives with different mechanisms of action and potential advantages.